|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, AKR1C3 immunostaining was significantly stronger in CRPC tissues than in HNPC tissues in the same patients (<i>p</i> = 0.0234).
|
31052459 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKR1C3 inhibitors have been used clinically for CRPC and AML and can be used to probe its pluripotency.
|
30012349 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AKR1C3 was overexpressed in more aggressive PCa cell lines regardless of the androgen receptor status.
|
30139661 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we demonstrate the antineoplastic activity of a potent, isoform-selective and hydrolytically stable AKR1C3 inhibitor (<i>E</i>)-3-(4-(3-methylbut-2-en-1-yl)-3-(3-phenylpropanamido)phenyl)acrylic acid (<b>KV-37</b>), which reduces prostate cancer cell growth <i>in vitro</i> and <i>in vivo</i> and sensitizes CRPC cell lines (22Rv1 and LNCaP1C3) toward the antitumor effects of enzalutamide.
|
29891491 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together this study therefore demonstrates that the ratio of AKR1C3:17βHSD2 is more important than AKR1C3 expression alone in determining intratumoral androgen levels and that 11-oxygenated androgens may play a bigger role in CRPC than previously anticipated.
|
29936123 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKR1C3 is a promising therapeutic target for castration-resistant prostate cancer.
|
30429100 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKR1C3 inhibitors may have distinct advantages over existing therapeutics for the treatment of castration resistant prostate cancer, breast cancer and acute myeloid leukemia.
|
28895472 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CRPC cells showed an increased expression of ACSL3 and an expression pattern of AKR1C3 and UGT2B similar to ACSL3-overexpressing cells.
|
28771887 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting AKR1C3 is a potential target for treating castration-resistant prostate cancer (CRPC).
|
27163852 |
2016 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elucidation of ERG regulation of ABEs in CRPC may help to stratify TMPRSS2-ERG fusion-positive prostate cancer patients in the clinic for anti-androgen receptor-driven therapies; and AKR1C3 may serve as a valuable therapeutic target in the treatment of CRPC.
|
25754347 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This makes AKR1C3 a target for the treatment of CRPC.
|
23432095 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AKR1C3 overexpression promotes the growth of both androgen-dependent prostate cancer and CRPC xenografts, with concomitant reactivation of androgen signaling.
|
23995860 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aldo-keto reductase 1C3 (AKR1C3; type 5 17β-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated in the intratumoral biosynthesis of testosterone and 5α-dihydrotestosterone.
|
22263837 |
2012 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PCa and CRPC often depend on intratumoral androgen biosynthesis and upregulation of AKR1C3 could contribute to intracellular synthesis of AR ligands and stimulation of proliferation through AR signaling.
|
22265960 |
2012 |